Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
复制标题
DOI：
10.1155/2015/157201
复制
发表时间：
2015
影响因子：
4.3
通讯作者：
Zhan S
中科院分区：
文献类型：
--
作者：
Sun F;Chai S;Li L;Yu K;Yang Z;Wu S;Zhang Y;Ji L;Zhan S
为评价胰升糖素样肽-1受体激动剂(GLP-1RAS)对2型糖尿病(T2 DM)患者的减肥效果，进行了网络Meta分析。检索Medline、EMBASE、Cochrane图书馆和ClinicalTrials.gov，检索时间为1950年至2013年10月。如果涉及GLP-1RAS的随机对照试验(RCT)提供了有关体重的信息，则包括在内。共纳入51个随机对照试验，共有17521名参与者参加。51例随机对照试验的平均持续时间为31周。与每日两次的埃克塞那肽5 μg(EX5BID)、利拉鲁肽0.6 μmg每日一次(LIR0.6QD)、利拉鲁肽1.2 mg每日一次(LIR1.2QD)和安慰剂治疗相比，埃克塞那肽10 g每日两次(EX10BID)减轻体重，平均差异为−1.07 kg(95%CI：−2.41，−0.02)，−2.38 kg(95%CI：−3.71，−1.06)，−1.62 kg(95%CI：−2.79，−为0.43)，−为1.92 kg(95%CI：−2.61，−1.24)。服用利拉鲁肽-1.8QD的患者体重减轻达到统计学意义(−1.43 千克(95%可信区间：−2.73，−0.15)比LIR1.2QD和−0.98 千克(95%可信区间：−1.94，−0.02)与安慰剂相比。网络荟萃分析发现，与其他传统降糖药相比，EX10BID、LIR1.8QD和EX2QW获得了更高比例的减肥患者。我们的结果表明，与传统降糖药物相比，GLP-1 RAS是有希望的体重控制候选药物，EX10BID、LIR1.8QD和EX2QW是排名前三的药物。
To evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta-analysis was conducted. MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched from 1950 to October 2013. Randomized controlled trials (RCTs) involving GLP-1 RAs were included if they provided information on body weight. A total of 51 RCTs were included and 17521 participants were enrolled. The mean duration of 51 RCTs was 31 weeks. Exenatide 10 μg twice daily (EX10BID) reduced weight compared with exenatide 5 μg twice daily (EX5BID), liraglutide 0.6 mg once daily (LIR0.6QD), liraglutide—1.2 mg once daily (LIR1.2QD), and placebo treatment, with mean differences of −1.07 kg (95% CI: −2.41, −0.02), −2.38 kg (95% CI: −3.71, −1.06), −1.62 kg (95% CI: −2.79, −0.43), and −1.92 kg (95% CI: −2.61, −1.24), respectively. Reductions of weight treated with liraglutide—1.8 mg once daily (LIR1.8QD) reach statistical significance (−1.43 kg (95% CI: −2.73, −0.15)) versus LIR1.2QD and (−0.98 kg (95% CI: −1.94, −0.02)) versus placebo. Network meta-analysis found that EX10BID, LIR1.8QD, and EX2QW obtained a higher proportion of patients with weight loss than other traditional hypoglycemic agents. Our results suggest GLP-1 RAs are promising candidates for weight control in comparison with traditional hypoglycemic drugs, and EX10BID, LIR1.8QD, and EX2QW rank the top three drugs.
登录
查看更多内容
影响因子：
2.7
作者：
Shyangdan DS;Royle PL;Clar C;Sharma P;Waugh NR
通讯作者：
Waugh NR
DOI：
10.1016/s0889-8529(03)00071-9
发表时间：
2003-12-01
影响因子：
4.5
作者：
Maggio, CA;Pi-Sunyer, FX
通讯作者：
Pi-Sunyer, FX
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
4.7
作者：
Kanoski SE;Rupprecht LE;Fortin SM;De Jonghe BC;Hayes MR
通讯作者：
Hayes MR
影响因子：
2.9
作者：
Tzefos, Maria;Harris, Kira;Brackett, Adriane
通讯作者：
Brackett, Adriane